GP2-Isoformen und deren Verwendung bei der Autoantikörpererfassung
Anmelder: GA Generic Assays GmbH 🇩🇪
Details
- Veröffentlichungs-Nr.
- EP2913675
- Aktenzeichen
- EP15156756
- Anmeldetag
- 26. Februar 2015
- Veröffentlichung
- 12. Februar 2020
- Erteilung
- 12. Februar 2020
- Rechtsraum
- EP
- IPC
- G01N33/68
Abstract
The invention relates to a method for binding or capturing autoantibodies directed to various Glycoprotein 2 (GP2) isoforms. In particular the invention provides an in vitro method for the diagnosis of an autoimmune disorder by the detection of autoantibodies that bind one or more isoforms of GP2. The invention is characterised by the provision of multiple isoforms of GP2 as autoantibody targets and encompasses the practical utilisation of the finding that the isoform specificity of anti-GP2 autoantibodies enables determination of particular autoimmune diseases. The invention also provides a kit developed for carrying out the claimed method. The present invention is useful for determining whether a sample from an individual comprises autoantibodies associated with an autoimmune disease, and for differentiating between multiple autoimmune diseases that exhibit similar symptoms, such as Celiac disease (CeD), Crohn's disease (CD) and/or ulcerative colitis (UC).
Anmelder
- Firma
- GA Generic Assays GmbH
- Land
- 🇩🇪 Deutschland
Fachgebiete
-
Hertin und Partner Rechts- und Patentanwälte PartG mbB
Hertin und Partner Rechts- und Patentanwälte PartG mbB · Berlin